TY - JOUR
T1 - Heart regeneration with human pluripotent stem cells
T2 - Prospects and challenges
AU - Jiang, Yuqian
AU - Lian, Xiaojun Lance
N1 - Funding Information:
This work was supported by Penn State College of Engineering ENGINE Grant to X.L. Penn State Startup funding to X.L. and USA NIH R21EB026035 to X.L.
Funding Information:
This work was supported by Penn State College of Engineering ENGINE Grant to X.L., Penn State Startup funding to X.L., and USA NIH R21EB026035 to X.L. Appendix A
Publisher Copyright:
© 2020
PY - 2020/3
Y1 - 2020/3
N2 - Cardiovascular disease, ranging from congenital heart disease to adult myocardial infarction, is the leading cause of death worldwide. In pursuit of reliable cardiovascular regenerative medicine, human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), offer plenty of potential cell-based applications. HPSCs are capable of proliferating indefinitely in an undifferentiated state, and are also pluripotent, being able to differentiate into virtually any somatic cell types given specific stepwise cues, thus representing an unlimited source to generate functional cardiovascular cells for heart regeneration. Here we recapitulated current advances in developing efficient protocols to generate hPSC-derived cardiovascular cell lineages, including cardiomyocytes, endothelial cells, and epicardial cells. We also discussed applications of hPSC-derived cells in combination with compatible bioactive materials, promising trials of cell transplantation in animal models of myocardial infarction, and potential hurdles to bring us closer to the ultimate goal of cell-based heart repair.
AB - Cardiovascular disease, ranging from congenital heart disease to adult myocardial infarction, is the leading cause of death worldwide. In pursuit of reliable cardiovascular regenerative medicine, human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), offer plenty of potential cell-based applications. HPSCs are capable of proliferating indefinitely in an undifferentiated state, and are also pluripotent, being able to differentiate into virtually any somatic cell types given specific stepwise cues, thus representing an unlimited source to generate functional cardiovascular cells for heart regeneration. Here we recapitulated current advances in developing efficient protocols to generate hPSC-derived cardiovascular cell lineages, including cardiomyocytes, endothelial cells, and epicardial cells. We also discussed applications of hPSC-derived cells in combination with compatible bioactive materials, promising trials of cell transplantation in animal models of myocardial infarction, and potential hurdles to bring us closer to the ultimate goal of cell-based heart repair.
UR - http://www.scopus.com/inward/record.url?scp=85077739110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077739110&partnerID=8YFLogxK
U2 - 10.1016/j.bioactmat.2020.01.003
DO - 10.1016/j.bioactmat.2020.01.003
M3 - Review article
C2 - 31989061
AN - SCOPUS:85077739110
SN - 2452-199X
VL - 5
SP - 74
EP - 81
JO - Bioactive Materials
JF - Bioactive Materials
IS - 1
ER -